<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987596</url>
  </required_header>
  <id_info>
    <org_study_id>2013-062</org_study_id>
    <secondary_id>NCI-2013-02001</secondary_id>
    <secondary_id>2013-062</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT01987596</nct_id>
  </id_info>
  <brief_title>Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer</brief_title>
  <official_title>Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies flexible administration of filgrastim after&#xD;
      combination chemotherapy to see how well it works compared to fixed administration of&#xD;
      filgrastim in decreasing side effects of chemotherapy in younger patients with cancer. Cancer&#xD;
      chemotherapy frequently results in neutropenia (low blood counts) when patients are&#xD;
      susceptible to severe infections. A medicine called G-CSF (filgrastim) stimulates bone marrow&#xD;
      and daily filgrastim shots are commonly used to shorten neutropenic periods and decrease&#xD;
      infections after chemotherapy. Since filgrastim is customarily used on a fixed schedule&#xD;
      starting early after chemotherapy and there are data that early doses may not be needed, this&#xD;
      study tests new flexible schedule of filgrastim to optimize its use by reducing the number of&#xD;
      painful shots, cost of treatment, and filgrastim side effects in children with cancer&#xD;
      receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the effect of flexible vs. fixed administration of G-CSF (filgrastim) on the&#xD;
      parameters of hematological recovery including duration of absolute neutrophil count (ANC) &lt;&#xD;
      500/uL; time to ANC recovery &gt;= 1,000/uL and time to platelet recovery &gt;= 75,000/uL in&#xD;
      children receiving myelotoxic chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the effect of flexible vs. fixed administration of G-CSF on the incidence of&#xD;
      febrile neutropenia and number of hospital days on antibiotics following myelotoxic&#xD;
      chemotherapy.&#xD;
&#xD;
      II. To evaluate the number of days of platelet transfusion events after chemotherapy cycles&#xD;
      with flexible vs. fixed administration of G-CSF.&#xD;
&#xD;
      III. To evaluate on the incidence and duration of G-CSF-related side effects including&#xD;
      extremities/back pain and headaches after chemotherapy courses followed by flexible vs. fixed&#xD;
      administration of G-CSF.&#xD;
&#xD;
      IV. To evaluate the peripheral blood progenitor responses and subsets of progenitor cells&#xD;
      (cluster of differentiation [CD]34/41/61/117/10/19/11b/33) to chemotherapy followed by&#xD;
      flexible vs. fixed administration of G-CSF.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CHEMOTHERAPY: Depending on their diagnosis patients are assigned to 1 of 3 chemotherapy&#xD;
      regimens.&#xD;
&#xD;
      ICE: Patients receive etoposide intravenously (IV) over 1 hour on days 1-3, ifosfamide IV&#xD;
      over 3 hours on days 1-3, and carboplatin IV over 1 hour on day 4. Patients with recurrent&#xD;
      Hodgkin lymphoma receive etoposide and ifosfamide on days 1-3 and carboplatin on day 3.&#xD;
&#xD;
      ICT: Patients receive topotecan hydrochloride IV over 30 minutes on days 1-3, and ifosfamide&#xD;
      and carboplatin as in ICE.&#xD;
&#xD;
      OPEC: Patients receive vincristine sulfate on days 1, 8, and 15; etoposide IV over 1 hour on&#xD;
      days 1-3; cyclophosphamide IV over 1 hour on days 1-2; and cisplatin IV over 6 hours on day&#xD;
      4.&#xD;
&#xD;
      For all chemotherapy regimens, treatment repeats every 21 days for 2 courses. Patients are&#xD;
      then randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I (fixed filgrastim): Patients receive filgrastim subcutaneously (SC) once daily (QD)&#xD;
      started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least&#xD;
      1,000/uL post nadir.&#xD;
&#xD;
      ARM II (flexible filgrastim): Patients receive filgrastim SC QD started on the first day&#xD;
      after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least&#xD;
      1,000/uL post nadir.&#xD;
&#xD;
      After completion of the first filgrastim treatment, patients cross-over to the other&#xD;
      filgrastim arm and repeat the same course of chemotherapy as before. After completion of the&#xD;
      second filgrastim treatment, chemotherapy treatment may continue for up to 5 (OPEC) or 6&#xD;
      (ICE, ICT) courses in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to ANC Greater Than or Equal to 1,000/uL From the Start of Chemotherapy</measure>
    <time_frame>From the start of the course until the first date the ANC reaches &gt;= 1,000/uL post nadir, assessed up to 1 year</time_frame>
    <description>Time in days until absolute neutrophil count (ANC) recovery to greater than or equal to 1,000/uL from the start of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Febrile Neutropenia</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>occurrence of febrile neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative GCSF Dose</measure>
    <time_frame>up until engraftment</time_frame>
    <description>Cumulative GCSF dose - number of GCSF injections until ANC recovery greater than or equal to 1,000/uL from the start of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to First G-CSF Dose</measure>
    <time_frame>time to ANC 1000</time_frame>
    <description>Time (in days) to first G-CSF dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Medulloblastoma</condition>
  <condition>Childhood Pineoblastoma</condition>
  <condition>Childhood Soft Tissue Sarcoma</condition>
  <condition>Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Neuroblastoma</condition>
  <condition>Osteosarcoma</condition>
  <condition>Retinoblastoma</condition>
  <condition>Wilms Tumor and Other Childhood Kidney Tumors</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I (fixed filgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (flexible filgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)</description>
    <arm_group_label>Arm I (fixed filgrastim)</arm_group_label>
    <arm_group_label>Arm II (flexible filgrastim)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have or have had at initial diagnosis, histologic proof of their&#xD;
             malignancy; young children with primary embryonal brain tumor treated according to&#xD;
             Head Start protocol are eligible; subjects with bone marrow involvement are NOT&#xD;
             eligible for study&#xD;
&#xD;
          -  Patients will receive repeated cycles of identical chemotherapy that will likely&#xD;
             result in grades III-IV hematological toxicity; patients will be treated outside of&#xD;
             Children's Oncology Group (COG) protocols with specific requirements for schedule of&#xD;
             G-CSF administration; the following categories of patients treated at Children's&#xD;
             Hospital of Michigan are eligible for this study:&#xD;
&#xD;
               -  Patients with brain tumors treated according to Head Start II protocol with&#xD;
                  vincristine, etoposide, cyclophosphamide, and cisplatin (OPEC) chemotherapy;&#xD;
&#xD;
               -  Patients with recurrent Hodgkin lymphoma treated with ICE (ifosfamide,&#xD;
                  carboplatin, etoposide) chemotherapy;&#xD;
&#xD;
               -  Patients with recurrent solid tumors including sarcomas, Wilms' tumor,&#xD;
                  neuroblastomas, or brain tumors treated with high dose ICE or ICT (ifosfamide,&#xD;
                  carboplatin, topotecan) chemotherapy&#xD;
&#xD;
               -  Patients with UH Wilms' tumor treated with CE (cyclophosphamide, etoposide);&#xD;
                  patients with neuroblastoma treated with CE (carboplatin, etoposide);&#xD;
&#xD;
               -  Patients with soft tissue sarcomas treated with IA (ifosfamide, doxorubicin);&#xD;
&#xD;
               -  Patients with osteosarcoma treated with high dose ifosfamide&#xD;
&#xD;
          -  Subjects must have fully recovered from the toxic effects of any prior therapy; at&#xD;
             least 3 weeks should have elapsed since the last dose of chemotherapy (6 weeks in the&#xD;
             case of nitrosourea containing therapy); subjects must have recovered from previous&#xD;
             colony-stimulating factor therapy and have been off colony-stimulating factors (G-CSF,&#xD;
             granulocyte macrophage colony-stimulating factor [GM-CSF], interleukin [IL]-11) for&#xD;
             more than 10 days and off erythropoietin for 30 days&#xD;
&#xD;
          -  ANC &gt; 1000/uL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/uL&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate (GFR) which is greater than or&#xD;
             equal to 70 ml/min/1.73 m^2&#xD;
&#xD;
          -  Bilirubin less than 1.5 x normal limit (NL)&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) less than 2.5 x NL for age&#xD;
&#xD;
          -  Subjects should have a normal ejection fraction (per institutional limits), no&#xD;
             evidence of cardiac arrhythmias requiring therapy, and a fractional shortening of &gt;&#xD;
             28%&#xD;
&#xD;
          -  All subjects must have a life expectancy of 12 weeks or more&#xD;
&#xD;
          -  Diagnostic categories&#xD;
&#xD;
               -  Sarcoma (soft tissue and bone)&#xD;
&#xD;
               -  Kidney tumors&#xD;
&#xD;
               -  Brain tumors&#xD;
&#xD;
               -  Other solid tumors (gonadal and germ cell tumors, retinoblastoma, neuroblastoma,&#xD;
                  and miscellaneous tumors)&#xD;
&#xD;
               -  Hodgkin lymphoma&#xD;
&#xD;
          -  Performance status must be &gt; 60 from Lansky (age 1 to 16) or Karnofsky (age &gt; 16)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any of the following will NOT be eligible for study:&#xD;
&#xD;
               -  Bone marrow involvement&#xD;
&#xD;
               -  Active myelogenous leukemia, or history of myelogenous leukemia&#xD;
&#xD;
               -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxim Yankelevich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <results_first_submitted>October 2, 2020</results_first_submitted>
  <results_first_submitted_qc>October 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2020</results_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Maxim Yankelevich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT01987596/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Fixed Flexible Filgrastim Schedule)</title>
          <description>Period 1 Fixed: Patients receive filgrastim SC QD once daily started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
Period 2 Flexible: Patients receive filgrastim:SC once starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Flexible Fixed Filgrastim Schedule)</title>
          <description>Period 1 Flexible: Patients receive filgrastim SC QD started on the first day after chemotherapy and on any day when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
Period 2 Fixed: Patients receive filgrastim: given SC once daily starting on day 1 after chemotherapy in and daily thereafter until ANC reaches at least 1,000/uL post nadir.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease; missing all period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who completed period 2</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Fixed Flexible Filgrastim Schedule)</title>
          <description>Period 1 Fixed: Patients receive filgrastim SC QD once daily started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
Period 2 Flexible: Patients receive filgrastim:SC once starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Flexible Fixed Filgrastim Schedule)</title>
          <description>Period 1 Flexible: Patients receive filgrastim SC QD started on the first day after chemotherapy and on any day when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
Period 2 Fixed: Patients receive filgrastim: given SC once daily starting on day 1 after chemotherapy in and daily thereafter until ANC reaches at least 1,000/uL post nadir.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="6" upper_limit="22"/>
                    <measurement group_id="B2" value="11" lower_limit="5" upper_limit="22"/>
                    <measurement group_id="B3" value="14" lower_limit="5" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days to ANC Greater Than or Equal to 1,000/uL From the Start of Chemotherapy</title>
        <description>Time in days until absolute neutrophil count (ANC) recovery to greater than or equal to 1,000/uL from the start of chemotherapy</description>
        <time_frame>From the start of the course until the first date the ANC reaches &gt;= 1,000/uL post nadir, assessed up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed</title>
            <description>Mean of time to ANC1000 during period participants were on fixed regimen</description>
          </group>
          <group group_id="O2">
            <title>Flexible</title>
            <description>Mean of time to ANC1000 during period participants were on flexible regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Days to ANC Greater Than or Equal to 1,000/uL From the Start of Chemotherapy</title>
          <description>Time in days until absolute neutrophil count (ANC) recovery to greater than or equal to 1,000/uL from the start of chemotherapy</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="15.0" upper_limit="17.1"/>
                    <measurement group_id="O2" value="16.7" lower_limit="15.7" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Febrile Neutropenia</title>
        <description>occurrence of febrile neutropenia</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Each patient server as his/her own control</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed</title>
            <description>Incidence duriing time patient was on fixed schedule</description>
          </group>
          <group group_id="O2">
            <title>Flexible</title>
            <description>Incidence duriing time patient was on flexible schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Febrile Neutropenia</title>
          <description>occurrence of febrile neutropenia</description>
          <population>Each patient server as his/her own control</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative GCSF Dose</title>
        <description>Cumulative GCSF dose - number of GCSF injections until ANC recovery greater than or equal to 1,000/uL from the start of chemotherapy</description>
        <time_frame>up until engraftment</time_frame>
        <population>Patients who had data for period 2</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Filgrastim</title>
            <description>Patients receive filgrastim daily SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.</description>
          </group>
          <group group_id="O2">
            <title>Flexible Filgrastim</title>
            <description>Patients receive filgrastim SC QD started on the first day after chemotherapy and on any day ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative GCSF Dose</title>
          <description>Cumulative GCSF dose - number of GCSF injections until ANC recovery greater than or equal to 1,000/uL from the start of chemotherapy</description>
          <population>Patients who had data for period 2</population>
          <units>Doses</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="9.6" upper_limit="11.2"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.5" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>two-period crossover design analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to First G-CSF Dose</title>
        <description>Time (in days) to first G-CSF dose</description>
        <time_frame>time to ANC 1000</time_frame>
        <population>All participants with period 2 data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Fixed Filgrastim)</title>
            <description>Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and continued daily until ANC reaches at least 1,000/uL post nadir.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Flexible Filgrastim)</title>
            <description>Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to First G-CSF Dose</title>
          <description>Time (in days) to first G-CSF dose</description>
          <population>All participants with period 2 data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.5" upper_limit="5.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="8.4" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 treatment, 2 periiod cross-over analysis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Nothing to mention</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Fixed Filgrastim)</title>
          <description>Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
filgrastim: Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Flexible Filgrastim)</title>
          <description>Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.&#xD;
filgrastim: Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>GCSF related pain (headaches, back or extremities pain)</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>GCSF related pain including headaches, back and extremities pain</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maxim Yankelevich</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-745-5515</phone>
      <email>myankele@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

